NeudertC, OliverDJ, WasnerM, BorasioG: The course of the terminal phase in patients with amyotrophic lateral sclerosis. J Neurol, 2001; 248:612–616.
2.
MillerRG, JacksonCE, KasarskisEJ, et al.: Practice parameter update: The care of the patient with amyotrophic lateral sclerosis: Drug, nutritional, and respiratory therapies (an evidence-based review): Report of the Quality Standards Subcommittee of the American Academy of Neurology [published correction appears in Neurology. 2009;73:2134] [published correction appears in Neurology. 2010; 74:781]. Neurology, 2009; 74:1218–1226.
3.
WestenengHJ, DebrayTPA, VisserAE, et al.: Prognosis for patients with amyotrophic lateral sclerosis: Development and validation of a personalised prediction model. Lancet Neurol, 2018; 17:423–433.
XuL, HeB, ZhangY, et al.: Prognostic models for amyotrophic lateral sclerosis: A systematic review. J Neurol, 2021; 268:3361–3370.
7.
McCluskeyL, HousemanG: Medicare hospice referral criteria for patients with amyotrophic lateral sclerosis: A need for improvement. J Palliat Med, 2004; 7:47–53.
8.
BackAL, ArnoldRM: Discussing prognosis: How much do you want to know? Talking to patients who are prepared for explicit information. J Clin Oncol, 2006; 24:4209–4213.
9.
BackAL, ArnoldRM: Discussing prognosis: How much do you want to know? Talking to patients who do not want information or who are ambivalent. J Clin Oncol, 2006; 24:4214–4217.
10.
Van EenennaamRM, KruithofWJ, van EsMA, et al.: Discussing personalized prognosis in amyotrophic lateral sclerosis: Development of a communication guide. BMC Neurol, 2020; 20:446.